open access

Vol 21, No 1 (2018)
Reviews
Published online: 2017-12-27
Submitted: 2017-12-04
Accepted: 2017-12-20
Get Citation

The use of 67Ga scintigraphy in patients with sarcoidosis

Ewa Malinowska, Anna Doboszyńska, Anna Śliwińska, John R. Buscombe, Grzegorz Kulesza, Beata Moczulska, Jarosław B. Ćwikła
DOI: 10.5603/NMR.a2018.0007
·
Pubmed: 29319141
·
Nucl. Med. Rev 2018;21(1):59-65.

open access

Vol 21, No 1 (2018)
Reviews
Published online: 2017-12-27
Submitted: 2017-12-04
Accepted: 2017-12-20

Abstract

Sarcoidosis is a systemic disease of unknown aetiology characterised by the formation of noncaseating granulomas in various organs and tissues. The various imaging modalities that are useful in the investigation of lesions, staging and establishing indications for treatment include: conventional radiography, CT, MRI, and scintigraphy with 67Ga, 201Tl, 99mTc sestamibi, and somatostatin receptor scintigraphy (SRS) as well as 18F-FDG-PET/CT. This paper discusses the most commonly used technique of the scintigraphic, gallium (67Ga) citrate) and its role in the evaluation and monitoring of patients with sarcoidosis.

Abstract

Sarcoidosis is a systemic disease of unknown aetiology characterised by the formation of noncaseating granulomas in various organs and tissues. The various imaging modalities that are useful in the investigation of lesions, staging and establishing indications for treatment include: conventional radiography, CT, MRI, and scintigraphy with 67Ga, 201Tl, 99mTc sestamibi, and somatostatin receptor scintigraphy (SRS) as well as 18F-FDG-PET/CT. This paper discusses the most commonly used technique of the scintigraphic, gallium (67Ga) citrate) and its role in the evaluation and monitoring of patients with sarcoidosis.

Get Citation

Keywords

sarcoidosis, 67Ga scintigraphy, SPECT/CT

About this article
Title

The use of 67Ga scintigraphy in patients with sarcoidosis

Journal

Nuclear Medicine Review

Issue

Vol 21, No 1 (2018)

Pages

59-65

Published online

2017-12-27

DOI

10.5603/NMR.a2018.0007

Pubmed

29319141

Bibliographic record

Nucl. Med. Rev 2018;21(1):59-65.

Keywords

sarcoidosis
67Ga scintigraphy
SPECT/CT

Authors

Ewa Malinowska
Anna Doboszyńska
Anna Śliwińska
John R. Buscombe
Grzegorz Kulesza
Beata Moczulska
Jarosław B. Ćwikła

References (46)
  1. Rao DA, Dellaripa PF. Extrapulmonary manifestations of sarcoidosis. Rheum Dis Clin North Am. 2013; 39(2): 277–297.
  2. McKusick KA, Soin JS, Ghiladi A, et al. Gallium 67 accumulation in pulmonary sarcoidosis. JAMA. 1973; 223(6): 688.
  3. Karkavitsas N, Damilakis J, Tzanakis N, et al. Effectiveness of Tc-99m sestamibi compared to Ga-67 in patients with pulmonary sarcoidosis. Clin Nucl Med. 1997; 22(11): 749–751.
  4. Stoffey RD, Leckie RG, Buckner AB. Incidental finding of pulmonary sarcoidosis during stress thallium imaging. Clin Nucl Med. 1992; 17(11): 910–912.
  5. Oztürk E, Günalp B, Ozgüven M, et al. The visualization of granulomatous disease with somatostatin receptor scintigraphy. Clin Nucl Med. 1994; 19(2): 129–132.
  6. Nishiyama Y, Yamamoto Y, Furkunaga K, et al. Comparative Evaluation of 18F-FDG PET and 67Ga Scintigraphy in Patients with Sarcoidosis. J Nucl Med. 2006; 47: 1571–1576.
  7. Vorselaars ADM, van Moorsel CHM, Zanen P, et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med. 2015; 109(2): 279–285.
  8. Rømer FK. Clinical and biochemical aspects of sarcoidosis. With special reference to angiotensin-converting enzyme (ACE). Acta Med Scand Suppl. 1984; 690: 3–96.
  9. Beaumont D, Herry JY, Sapene M, et al. Gallium-67 in the evaluation of sarcoidosis: correlations with serum angiotensin-converting enzyme and bronchoalveolar lavage. Thorax. 1982; 37(1): 11–18.
  10. Lavender JP, Lowe J, Barker JR, et al. Gallium 67 citrate scanning in neoplastic and inflammatory lesions. Br J Radiol. 1971; 44(521): 361–366.
  11. Nakano S, Hasegawa Y, Ibuka K, et al. Clinical study of urinary excretion of Ga-67. Clin Nucl Med. 1990; 15(4): 260–262.
  12. Sulavik SB, Palestro CJ, Spencer RP, et al. Extrapulmonary sites of radiogallium accumulation in sarcoidosis. Clin Nucl Med. 1990; 15(12): 876–878.
  13. Israel HL, Albertine KH, Park CH, et al. Whole-body gallium 67 scans. Role in diagnosis of sarcoidosis. Am Rev Respir Dis. 1991; 144(5): 1182–1186.
  14. Ishii S, Miyajima M, Sakuma K, et al. Comparison between sarcoidosis and IgG4-related disease by whole-body 67Ga scintigraphy. Nucl Med Commun. 2013; 34(1): 13–18.
  15. Infante JR, Pacheco C, Torres-Avisbal M, et al. [Pulmonary activity in sarcoidosis: 67Ga uptake quantification and plasma determination of 1,25-dihydroxyvitamin D)]. Rev Esp Med Nucl. 2002; 21(4): 275–280.
  16. Kramer EL, Sanger JH, Garay SM, et al. Diagnostic implications of Ga-67 chest-scan patterns in human immunodeficiency virus-seropositive patients. Radiology. 1989; 170(3 Pt 1): 671–676.
  17. Rodrigues T, Rocha E, Barcelos A. Ocular and parotid sarcoidosis - panda sign. Acta Reumatol Port. 2014; 39(4): 345–346.
  18. Prager E, Wehrschuetz M, Bisail B, et al. Comparison of 18F-FDG and 67Ga-citrate in sarcoidosis imaging. Nuklearmedizin. 2008; 47(1): 18–23.
  19. Ross AH, Herbert HM, Kabala J, et al. Lacrimal gland uptake of gallium (67Ga) citrate in patients without ocular pathology. Orbit. 2009; 28(2-3): 120–123.
  20. Tannen BL, Kolomeyer AM, Turbin RE, et al. Lacrimal gland uptake of (67)Ga-gallium citrate correlates with biopsy results in patients with suspected sarcoidosis. Ocul Immunol Inflamm. 2014; 22(1): 15–22.
  21. Kawashiri Sy, Nakamura H, Origuchi T, et al. A case of lacrimal sarcoidosis following interstitial pneumonia: imaging and management. Nihon Rinsho Meneki Gakkai Kaishi. 2015; 38(3): 164–168.
  22. Fayad F, Duet M, Orcel P, et al. Systemic sarcoidosis: the “leopard–man” sign. Joint Bone Spine. 2006; 73(1): 109–112.
  23. Yanagisawa N, Okamura T. Muscular Sarcoidosis Mimicking Soft Tissue Tumor. Intern Med. 2016; 55(1): 95–96.
  24. Suehiro S, Shiokawa S, Taniguchi S, et al. Gallium-67 scintigraphy in the diagnosis and management of chronic sarcoid myopathy. Clin Rheumatol. 2003; 22(2): 146–148.
  25. Chatani H, Tanaka M, Nagata T, et al. Guillain-Barré syndrome-like-onset neurosarcoidosis positive for immunoglobulin G anti-N-acetylgalactosaminyl-GD1a antibody. J Clin Neurosci. 2014; 21(1): 170–172.
  26. Zajicek JP, Scolding NJ, Foster O, et al. Central nervous system sarcoidosis--diagnosis and management. QJM. 1999; 92(2): 103–117.
  27. Fritz D, van de Beek D, Brouwer MC. Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis. BMC Neurol. 2016; 16(1): 220.
  28. Ibitoye RT, Wilkins A, Scolding NJ. Neurosarcoidosis: a clinical approach to diagnosis and management. J Neurol. 2017; 264(5): 1023–1028.
  29. Allard AB, Buscombe J, Kidd DP. The Role of Gallium (Ga-67) Scintigraphy in the Diagnosis of Sarcoidosis. Modern Research in Inflammation. 2014; 03(03): 99–107.
  30. Marvisi M. [Osteoarticular sarcoidosis]. Minerva Med. 1998; 89(5): 169–172.
  31. Kobak S, Sever F, Usluer O, et al. The clinical characteristics of sarcoid arthropathy based on a prospective cohort study. Ther Adv Musculoskelet Dis. 2016; 8(6): 220–224.
  32. Freyschmidt J, Freyschmidt P. Skelettsarkoidose. Der Radiologe. 2016; 56(10): 904–909.
  33. Palmucci S, Torrisi SE, Caltabiano DC, et al. Clinical and radiological features of extra-pulmonary sarcoidosis: a pictorial essay. Insights Imaging. 2016; 7(4): 571–587.
  34. Okabe T, Yakushiji T, Hiroe M, et al. Steroid pulse therapy was effective for cardiac sarcoidosis with ventricular tachycardia and systolic dysfunction. ESC Heart Fail. 2016; 3(4): 288–292.
  35. Erthal F, Juneau D, Lim SP, et al. Imaging of cardiac sarcoidosis. Q J Nucl Med Mol Imaging. 2016; 60(3): 252–263.
  36. Kouranos V, Wells AU, Sharma R, et al. Advances in radionuclide imaging of cardiac sarcoidosis. Br Med Bull. 2015; 115(1): 151–163.
  37. UMETANI K, ISHIHARA T, YAMAMOTO K, et al. Successfully Treated Complete Atrioventricular Block with Corticosteroid in a Patient with Cardiac Sarcoidosis. Usefulness of Gallium-67 and Thallium-201 Scintigraphy. Internal Medicine. 2000; 39(3): 245–248.
  38. Kiuchi S, Teraoka K, Koizumi K, et al. Usefulness of late gadolinium enhancement combined with MRI and 67-Ga scintigraphy in the diagnosis of cardiac sarcoidosis and disease activity evaluation. Int J Cardiovasc Imaging. 2007; 23(2): 237–241.
  39. Nakazawa Ai, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest. 2004; 126(4): 1372–1376.
  40. Maroz N, Field H. Necrotizing crescentic glomerulonephritis related to sarcoidosis: a case report. J Med Case Rep. 2015; 9: 282.
  41. Hishida E, Masuda T, Akimoto T, et al. Renal Failure Found during the Follow-up of Sarcoidosis: The Relevance of a Delay in the Diagnosis of Concurrent Hypercalcemia. Internal Medicine. 2016; 55(14): 1893–1898.
  42. Braun JJ, Imperiale A, Riehm S, et al. Imaging in sinonasal sarcoidosis: CT, MRI, 67Gallium scintigraphy and 18F-FDG PET/CT features. J Neuroradiol. 2010; 37(3): 172–181.
  43. Al-Suqri B, Al-Bulushi N. Gallium-67 Scintigraphy in the Era of Positron Emission Tomography and Computed Tomography: Tertiary centre experience. Sultan Qaboos University Medical Journal. 2015; 15(3): e338–343.
  44. Keijsers RG, Grutters JC, Thomeer M, et al. Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F-FDG PET. Q J Nucl Med Mol Imaging. 2011; 55(1): 66–71.
  45. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med. 2006; 47(10): 1571–1576.
  46. Jamar F, Buscombe J, Chiti A, et al. EANM/SNMMI guideline for 18F-FDG use in inflammation and infection. J Nucl Med. 2013; 54(4): 647–658.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., Świętokrzyska 73 street, 80–180 Gdańsk, Poland

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl